The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer-Reference-Cited by-同舟云学术

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer

Published:2022-04-08 Issue:19 Volume:11 Page:3581-3592
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Chen Hanxiao¹,Huang Dingzhi²^ORCID,Lin Gen³,Yang Xue¹,Zhuo Minglei¹,Chi Yujia¹,Zhai Xiaoyu¹,Jia Bo¹,Wang Jingjing¹,Wang Yuyan¹,Li Jianjie¹,An Tongtong¹,Wu Meina¹,Wang Ziping¹^ORCID,Zhao Jun¹^ORCID

Affiliation:

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Departments of Thoracic Medical Oncology Peking University Cancer Hospital and Institute Beijing China

2. Department of Thoracic Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Lung Cancer Center, Tianjin Cancer Institute and Hospital Tianjin Medical University Tianjin China

3. Departments of Thoracic Oncology, Fujian Cancer Hospital Fujian Medical University Cancer Hospital Fuzhou China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4739

Reference40 articles.

1. Report of cancer epidemiology in China, 2015;Zheng RS;Zhonghua Zhong Liu Za Zhi,2019

2. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

3. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

4. KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients

5. KRAS-Mutant non-small cell lung cancer: From biology to therapy

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential;Cancer Gene Therapy;2024-05-11

2. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma;European Journal of Cancer;2024-05

3. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment;Clinical and Translational Oncology;2024-04-16

4. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors;International Review of Cell and Molecular Biology;2024

5. CT‐based non‐invasive identification of the most common gene mutation status in patients with non‐small cell lung cancer;Medical Physics;2023-09-14